NO320392B1 - Fremgangsmate for fremstilling av parenteralt administrerbare mikrokapsler med vedvarende frigivelse, og mikropartikler ifolge denne fremgangsmaten - Google Patents

Fremgangsmate for fremstilling av parenteralt administrerbare mikrokapsler med vedvarende frigivelse, og mikropartikler ifolge denne fremgangsmaten Download PDF

Info

Publication number: NO320392B1
Authority: NO; Norway
Prior art keywords: active substance; coating; polymer; core particles; particles
Prior art date: 1995-10-19

Application number

NO19981558A

Other languages

English (en)

Norwegian (no)

Other versions

NO981558L (no

NO981558D0 (no

Inventor

Nils-Ove Gustafsson

Timo Laakso

Peter Fyhr

Monica Jonsson

Original Assignee

Jagotec Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-19

Filing date

1998-04-06

Publication date

2005-11-28

1998-04-06 Application filed by Jagotec Ag filed Critical Jagotec Ag

1998-04-06 Publication of NO981558L publication Critical patent/NO981558L/no

1998-04-06 Publication of NO981558D0 publication Critical patent/NO981558D0/no

2005-11-28 Publication of NO320392B1 publication Critical patent/NO320392B1/no

Links

238000000034 method Methods 0.000 title claims description 105
239000011859 microparticle Substances 0.000 title claims description 40
238000013268 sustained release Methods 0.000 title claims description 15
239000012730 sustained-release form Substances 0.000 title claims description 15
230000008569 process Effects 0.000 title claims description 14
239000003094 microcapsule Substances 0.000 title claims description 4
238000002360 preparation method Methods 0.000 title description 11
238000000576 coating method Methods 0.000 claims description 66
239000011248 coating agent Substances 0.000 claims description 64
229920000642 polymer Polymers 0.000 claims description 48
239000002245 particle Substances 0.000 claims description 45
239000003960 organic solvent Substances 0.000 claims description 35
102000004169 proteins and genes Human genes 0.000 claims description 35
108090000623 proteins and genes Proteins 0.000 claims description 35
239000013543 active substance Substances 0.000 claims description 32
239000007771 core particle Substances 0.000 claims description 32
239000000725 suspension Substances 0.000 claims description 30
239000000463 material Substances 0.000 claims description 28
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
238000004519 manufacturing process Methods 0.000 claims description 25
229920002472 Starch Polymers 0.000 claims description 23
235000019698 starch Nutrition 0.000 claims description 23
239000000839 emulsion Substances 0.000 claims description 22
229940088623 biologically active substance Drugs 0.000 claims description 12
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
239000000126 substance Substances 0.000 claims description 12
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 11
239000002904 solvent Substances 0.000 claims description 11
102000004196 processed proteins & peptides Human genes 0.000 claims description 7
108090000765 processed proteins & peptides Proteins 0.000 claims description 7
239000012736 aqueous medium Substances 0.000 claims description 6
239000003795 chemical substances by application Substances 0.000 claims description 6
239000004310 lactic acid Substances 0.000 claims description 6
235000014655 lactic acid Nutrition 0.000 claims description 6
239000007788 liquid Substances 0.000 claims description 6
239000000654 additive Substances 0.000 claims description 5
229940061720 alpha hydroxy acid Drugs 0.000 claims description 5
150000001280 alpha hydroxy acids Chemical class 0.000 claims description 5
230000000593 degrading effect Effects 0.000 claims description 5
238000001035 drying Methods 0.000 claims description 5
229920001577 copolymer Polymers 0.000 claims description 4
125000004122 cyclic group Chemical group 0.000 claims description 4
239000003381 stabilizer Substances 0.000 claims description 3
238000005406 washing Methods 0.000 claims description 3
229920000881 Modified starch Polymers 0.000 claims description 2
235000019426 modified starch Nutrition 0.000 claims description 2
239000004014 plasticizer Substances 0.000 claims description 2
229920001184 polypeptide Polymers 0.000 claims description 2
239000011257 shell material Substances 0.000 claims 5
239000004094 surface-active agent Substances 0.000 claims 1
239000000243 solution Substances 0.000 description 28
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 22
239000008107 starch Substances 0.000 description 21
239000000203 mixture Substances 0.000 description 17
239000004005 microsphere Substances 0.000 description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
239000003814 drug Substances 0.000 description 14
239000012071 phase Substances 0.000 description 14
229940079593 drug Drugs 0.000 description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
238000002347 injection Methods 0.000 description 12
239000007924 injection Substances 0.000 description 12
238000003756 stirring Methods 0.000 description 12
102000004877 Insulin Human genes 0.000 description 11
108090001061 Insulin Proteins 0.000 description 11
210000004369 blood Anatomy 0.000 description 11
239000008280 blood Substances 0.000 description 11
239000000872 buffer Substances 0.000 description 11
229940125396 insulin Drugs 0.000 description 11
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
239000008103 glucose Substances 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
239000011162 core material Substances 0.000 description 9
239000002202 Polyethylene glycol Substances 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
229920001223 polyethylene glycol Polymers 0.000 description 7
239000000047 product Substances 0.000 description 7
229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
235000017557 sodium bicarbonate Nutrition 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
238000009472 formulation Methods 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
239000004480 active ingredient Substances 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
239000006185 dispersion Substances 0.000 description 5
230000005611 electricity Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
239000007787 solid Substances 0.000 description 5
230000003068 static effect Effects 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
229920001688 coating polymer Polymers 0.000 description 4
230000001276 controlling effect Effects 0.000 description 4
229940088679 drug related substance Drugs 0.000 description 4
239000003995 emulsifying agent Substances 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
239000007789 gas Substances 0.000 description 4
238000007911 parenteral administration Methods 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000008186 active pharmaceutical agent Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
102000002265 Human Growth Hormone Human genes 0.000 description 2
108010000521 Human Growth Hormone Proteins 0.000 description 2
239000000854 Human Growth Hormone Substances 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
108010050144 Triptorelin Pamoate Proteins 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
102000004139 alpha-Amylases Human genes 0.000 description 2
108090000637 alpha-Amylases Proteins 0.000 description 2
229940024171 alpha-amylase Drugs 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
229920002988 biodegradable polymer Polymers 0.000 description 2
239000004621 biodegradable polymer Substances 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000002131 composite material Substances 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
238000004945 emulsification Methods 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000001087 glyceryl triacetate Substances 0.000 description 2
235000013773 glyceryl triacetate Nutrition 0.000 description 2
229920001519 homopolymer Polymers 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
238000005259 measurement Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000012460 protein solution Substances 0.000 description 2
235000013580 sausages Nutrition 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
238000001694 spray drying Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
229960002622 triacetin Drugs 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
108010069236 Goserelin Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000976075 Homo sapiens Insulin Proteins 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
239000004368 Modified starch Substances 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
229920003232 aliphatic polyester Polymers 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000000560 biocompatible material Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
235000019365 chlortetracycline Nutrition 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
238000010931 ester hydrolysis Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229940031098 ethanolamine Drugs 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
239000003337 fertilizer Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
239000008384 inner phase Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000010606 normalization Methods 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000008385 outer phase Substances 0.000 description 1
230000035699 permeability Effects 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
-1 polypropylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
238000004321 preservation Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
238000005549 size reduction Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
229960002372 tetracaine Drugs 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
239000001069 triethyl citrate Substances 0.000 description 1
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical group C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229960004418 trolamine Drugs 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
239000008307 w/o/w-emulsion Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229940033942 zoladex Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Physical Or Chemical Processes And Apparatus (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Manufacturing Of Micro-Capsules (AREA)

NO19981558A 1995-10-19 1998-04-06 Fremgangsmate for fremstilling av parenteralt administrerbare mikrokapsler med vedvarende frigivelse, og mikropartikler ifolge denne fremgangsmaten NO320392B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9503672A SE505146C2 (sv)	1995-10-19	1995-10-19	Partiklar för fördröjd frisättning
PCT/SE1996/001091 WO1997014408A1 (en)	1995-10-19	1996-09-03	Sustained release particles

Publications (3)

Publication Number	Publication Date
NO981558L NO981558L (no)	1998-04-06
NO981558D0 NO981558D0 (no)	1998-04-06
NO320392B1 true NO320392B1 (no)	2005-11-28

Family

ID=20399887

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19981558A NO320392B1 (no)	1995-10-19	1998-04-06	Fremgangsmate for fremstilling av parenteralt administrerbare mikrokapsler med vedvarende frigivelse, og mikropartikler ifolge denne fremgangsmaten

Country Status (16)

Country	Link
US (1)	US6120787A (de)
EP (3)	EP1716849A1 (de)
JP (1)	JP2000501380A (de)
KR (1)	KR100482262B1 (de)
AT (2)	ATE228826T1 (de)
AU (1)	AU699080B2 (de)
CZ (1)	CZ293059B6 (de)
DE (3)	DE69625240T2 (de)
DK (1)	DK0869774T3 (de)
ES (2)	ES2267637T3 (de)
HU (1)	HUP9901205A3 (de)
IL (1)	IL124052A (de)
NO (1)	NO320392B1 (de)
PT (1)	PT869774E (de)
SE (1)	SE505146C2 (de)
WO (1)	WO1997014408A1 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6045824A (en) *	1997-09-18	2000-04-04	Skyepharma Inc.	Sustained-release liposomal anesthetic compositions
US20070212422A1 (en) *	1999-11-10	2007-09-13	Manfred Keller	Dry powder for inhalation
US6458387B1 (en) *	1999-10-18	2002-10-01	Epic Therapeutics, Inc.	Sustained release microspheres
ES2169980B1 (es) *	1999-12-17	2003-11-01	Lipotec Sa	Microcapsulas para la liberacion prolongada de farmacos.
IT1318380B1 (it) *	2000-03-09	2003-08-25	Intercos Italiana	Polvere cosmetica rivestita.
US6495164B1 (en)	2000-05-25	2002-12-17	Alkermes Controlled Therapeutics, Inc. I	Preparation of injectable suspensions having improved injectability
ATE401095T1 (de) *	2000-05-26	2008-08-15	Frohwitter Bernhard	Mittel zum erhalten und/oder korrigieren der blutglukosekonzentration
US6824822B2 (en) *	2001-08-31	2004-11-30	Alkermes Controlled Therapeutics Inc. Ii	Residual solvent extraction method and microparticles produced thereby
CA2424896A1 (en)	2000-10-06	2002-04-11	Jagotec Ag	A controlled-release, parenterally administrable microparticle preparation
SE517421C2 (sv)	2000-10-06	2002-06-04	Bioglan Ab	Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav
SE517422C2 (sv)	2000-10-06	2002-06-04	Bioglan Ab	Farmaceutiskt acceptabel stärkelse
DE60138641D1 (de)	2000-10-27	2009-06-18	Baxter Healthcare Sa	Herstellung von mikrokügelchen
SE518007C2 (sv)	2000-11-16	2002-08-13	Bioglan Ab	Förfarande för framställning av mikropartiklar
US6967234B2 (en) *	2002-12-18	2005-11-22	Ethicon, Inc.	Alkyd-lactone copolymers for medical applications
US7030127B2 (en) *	2001-06-29	2006-04-18	Ethicon, Inc.	Composition and medical devices utilizing bioabsorbable polymeric waxes
US7034037B2 (en) *	2001-06-29	2006-04-25	Ethicon, Inc.	Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin
US20030064033A1 (en) *	2001-08-16	2003-04-03	Brown Larry R.	Propellant-based microparticle formulations
US7105181B2 (en)	2001-10-05	2006-09-12	Jagotec, Ag	Microparticles
AU2003216288B2 (en)	2002-02-13	2009-09-24	Duke University	Modulation of immune response by non-peptide binding stress response polypeptides
SE0201599D0 (sv)	2002-03-21	2002-05-30	Skyepharma Ab	Microparticles
US7326426B2 (en) *	2002-03-29	2008-02-05	Ethicon, Inc.	Compositions and medical devices utilizing bioabsorbable liquid polymers
US7005136B2 (en)	2002-03-29	2006-02-28	Ethicon, Inc.	Bone replacement materials utilizing bioabsorbable liquid polymers
US7368125B2 (en) *	2002-06-05	2008-05-06	Ethicon, Inc.	Amphiphilic polymers for medical applications
US7026374B2 (en) *	2002-06-25	2006-04-11	Aruna Nathan	Injectable microdispersions for medical applications
US7101566B2 (en) *	2002-06-28	2006-09-05	Ethicon, Inc.	Polymer coated microparticles for sustained release
CA2500661A1 (en)	2002-10-01	2004-04-15	Chiron Corporation	Anti-cancer and anti-infectious disease compositions and methods for using same
US6872799B2 (en)	2002-12-18	2005-03-29	Ethicon, Inc.	Functionalized polymers for medical applications
US6866860B2 (en)	2002-12-19	2005-03-15	Ethicon, Inc.	Cationic alkyd polyesters for medical applications
US20040120981A1 (en) *	2002-12-20	2004-06-24	Aruna Nathan	Crosslinked alkyd polyesters for medical applications
CA2510319A1 (en) *	2002-12-20	2004-07-15	Thomas J. Smith	High pressure compaction for pharmaceutical formulations
US7060299B2 (en) *	2002-12-31	2006-06-13	Battelle Memorial Institute	Biodegradable microparticles that stabilize and control the release of proteins
PT1638535E (pt) *	2003-06-26	2007-11-08	Mediolanum Pharmaceuticals Ltd	Implantes subcutâneos com libertação inicial de princípio activo limitada e subsequente sua libertação extensiva com variação linear
TWI357815B (en) *	2003-06-27	2012-02-11	Euro Celtique Sa	Multiparticulates
US20050142205A1 (en) *	2003-07-18	2005-06-30	Julia Rashba-Step	Methods for encapsulating small spherical particles prepared by controlled phase separation
US8075919B2 (en) *	2003-07-18	2011-12-13	Baxter International Inc.	Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
US20070092452A1 (en) *	2003-07-18	2007-04-26	Julia Rashba-Step	Methods for fabrication, uses, compositions of inhalable spherical particles
WO2005009375A2 (en) *	2003-07-22	2005-02-03	Baxter International Inc.	Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
KR100453273B1 (ko) *	2003-09-04	2004-10-15	주식회사 펩트론	초음파 이중공급노즐을 이용한 서방성 미립구의 제조 방법
US20060110423A1 (en) *	2004-04-15	2006-05-25	Wright Steven G	Polymer-based sustained release device
US7456254B2 (en) *	2004-04-15	2008-11-25	Alkermes, Inc.	Polymer-based sustained release device
CN1968700A (zh) *	2004-04-15	2007-05-23	阿尔克姆斯有限公司	聚合物基的持续释放装置
CN103393601A (zh)	2004-05-12	2013-11-20	巴克斯特国际公司	含有蛋白并在高浓度蛋白下显示可注射性的微球体
EP1765294B1 (de)	2004-05-12	2008-09-24	Baxter International Inc.	Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe
US8728525B2 (en)	2004-05-12	2014-05-20	Baxter International Inc.	Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
US7884085B2 (en) *	2004-05-12	2011-02-08	Baxter International Inc.	Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
EP1824460B1 (de) *	2004-11-10	2014-12-24	Tolmar Therapeutics, Inc.	Stabilisiertes polymer-abgabesystem
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
US8318210B2 (en)	2005-02-28	2012-11-27	Neos Therapeutics, Lp	Compositions and methods of making sustained release liquid formulations
MX2007013356A (es) *	2005-04-27	2008-03-26	Baxter Int	Microparticulas modificadas en la superficie y metodos de formacion y uso de las mismas.
US8017152B2 (en) *	2005-05-27	2011-09-13	Stratosphere Pharma Ab	Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
EP1726299A3 (de)	2005-05-27	2007-04-18	StratoSphere Pharma AB	Kerne und Mikrokapsel zur parenteralen Verabreichung sowie Verfahren zu deren Herstellung
US9693967B2 (en)	2005-09-07	2017-07-04	Southwest Research Institute	Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
WO2007030545A2 (en) *	2005-09-07	2007-03-15	Southwest Research Institute	Biodegradable microparticle pharmaceutical formulations exhibiting improved release rates
US20070092553A1 (en) *	2005-10-21	2007-04-26	Pfab Lp	Compositions and methods of making rapidly dissolving lonically masked formulations
US20080286375A1 (en) *	2005-11-15	2008-11-20	Amorepacific Corporation	Method for Preparing Sustained-Release Microparticles Comprising Sucrose Acetate Isobutyrate
GB0602897D0 (en) *	2006-02-13	2006-03-22	Jagotec Ag	Improvements In Or Relating To Dry Powder Inhaler Devices
US20070281031A1 (en) *	2006-06-01	2007-12-06	Guohan Yang	Microparticles and methods for production thereof
AU2007281737B2 (en)	2006-08-04	2013-09-19	Baxter Healthcare S.A.	Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
PL2359808T3 (pl)	2006-08-09	2013-10-31	Intarcia Therapeutics Inc	Osmotyczne systemy dostawcze i zespoły tłokowe
MX2009003661A (es) *	2006-10-06	2009-04-22	Baxter Int	Microcapsulas que contienen microparticulas modificadas en la superficie y metodos para formar y utilizar las mismas.
GB0622818D0 (en) *	2006-11-15	2006-12-27	Jagotec Ag	Improvements in or relating to organic compounds
GB0625303D0 (en) *	2006-12-19	2007-01-24	Jagotec Ag	Improvements in and relating to metered dose inhalers
WO2008118712A1 (en) *	2007-03-22	2008-10-02	Alkermes, Inc.	Coacervation process
GB0707612D0 (en)	2007-04-19	2007-05-30	Stratosphere Pharma Ab	Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
EP2157967B1 (de)	2007-04-23	2013-01-16	Intarcia Therapeutics, Inc	Suspensionsformulierungen insulinotroper peptide und ihre verwendung
CA2689101C (en) *	2007-05-30	2013-01-22	Neos Therapeutics, Lp	Modifying drug release in suspensions of ionic resin systems
US20080317865A1 (en) *	2007-06-20	2008-12-25	Alkermes, Inc.	Quench liquids and washing systems for production of microparticles
EP2240155B1 (de)	2008-02-13	2012-06-06	Intarcia Therapeutics, Inc	Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
US8323685B2 (en)	2008-08-20	2012-12-04	Baxter International Inc.	Methods of processing compositions containing microparticles
US8323615B2 (en)	2008-08-20	2012-12-04	Baxter International Inc.	Methods of processing multi-phasic dispersions
US8367427B2 (en)	2008-08-20	2013-02-05	Baxter International Inc.	Methods of processing compositions containing microparticles
EP3323423B1 (de)	2009-09-28	2020-06-17	Intarcia Therapeutics, Inc	Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
KR101331136B1 (ko)	2011-01-12	2013-11-26	아주대학교산학협력단	약물의 초기 과다 방출 제어를 위한 약물전달 제형 및 이의 제조방법
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN110575445B (zh)	2013-03-21	2023-08-18	优普顺药物公司美国分部	可注射的持续释放组合物及其用于治疗关节炎症及相关疼痛的方法
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es)	2015-06-03	2024-05-08	I2O Therapeutics Inc	Sistemas de colocación de implantes
AU2016343952A1 (en)	2015-10-27	2018-05-10	Eupraxia Pharmaceuticals Inc.	Sustained release formulations of local anesthetics
KR20240037175A (ko)	2016-05-16	2024-03-21	인타르시아 세라퓨틱스 인코포레이티드	글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
AU2018206539A1 (en)	2017-01-03	2019-07-18	Intarcia Therapeutics, Inc.	Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
KR102383448B1 (ko) *	2020-04-20	2022-04-06	한국화학연구원	락트산 또는 글리콜산을 포함하는 미립구형 서방출 제제 및 그의 제조방법

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3117027A (en) *	1960-01-08	1964-01-07	Wisconsin Alumni Res Found	Apparatus for coating particles in a fluidized bed
US3773919A (en) *	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4384975A (en) *	1980-06-13	1983-05-24	Sandoz, Inc.	Process for preparation of microspheres
US4479911A (en) *	1982-01-28	1984-10-30	Sandoz, Inc.	Process for preparation of microspheres and modification of release rate of core material
US4637905A (en) *	1982-03-04	1987-01-20	Batelle Development Corporation	Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones
CH661206A5 (fr) *	1983-09-23	1987-07-15	Debiopharm Sa	Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
US4623588A (en) *	1984-02-06	1986-11-18	Biotek, Inc.	Controlled release composite core coated microparticles
US4568559A (en) *	1984-02-06	1986-02-04	Biotek, Inc.	Composite core coated microparticles and process of preparing same
CA1256638A (en) *	1984-07-06	1989-06-27	Motoaki Tanaka	Polymer and its production
JP2551756B2 (ja) *	1985-05-07	1996-11-06	武田薬品工業株式会社	ポリオキシカルボン酸エステルおよびその製造法
US4666704A (en) *	1985-05-24	1987-05-19	International Minerals & Chemical Corp.	Controlled release delivery system for macromolecules
SE459005B (sv) *	1985-07-12	1989-05-29	Aake Rikard Lindahl	Saett att framstaella sfaeriska polymerpartiklar
AU7280387A (en) *	1986-04-07	1987-11-09	Rorer International (Overseas) Inc.	Method for the preparation of a sustained release pharmaceutical composition and the compostion prepared thereby
SE8701479L (sv) *	1987-04-09	1988-10-10	Carbomatrix Ab	Metod foer inneslutning av biologiskt verksamma preparat samt anvaendning daerav
US5019397A (en) *	1988-04-21	1991-05-28	Alza Corporation	Aqueous emulsion for pharmaceutical dosage form
US5275819A (en) *	1989-02-06	1994-01-04	Amer Particle Technologies Inc.	Drug loaded pollen grains with an outer coating for pulsed delivery
US5019400A (en) *	1989-05-01	1991-05-28	Enzytech, Inc.	Very low temperature casting of controlled release microspheres
CA2071867A1 (en) *	1989-11-06	1991-05-07	Edith Mathiowitz	Method for producing protein microspheres
FR2663207B1 (fr) *	1990-06-15	1993-04-30	Rhone Poulenc Nutrition Animal	Procede d'enrobage par un polymere ph sensible de principes actifs.
WO1992016191A1 (en) *	1991-03-25	1992-10-01	Fujisawa Pharmaceutical Co., Ltd.	Long-acting pharmaceutical preparation
KR100259989B1 (ko) *	1991-10-01	2000-08-01	모리다 가쓰라	서방성 마이크로캡슐 제제 및 그의 제조법
US5288502A (en) *	1991-10-16	1994-02-22	The University Of Texas System	Preparation and uses of multi-phase microspheres
JPH08503950A (ja) *	1992-12-02	1996-04-30	アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド	徐放性成長ホルモン含有マイクロスフェア
US5417982A (en) *	1994-02-17	1995-05-23	Modi; Pankaj	Controlled release of drugs or hormones in biodegradable polymer microspheres

1995
- 1995-10-19 SE SE9503672A patent/SE505146C2/sv not_active IP Right Cessation
1996
- 1996-09-03 ES ES01117830T patent/ES2267637T3/es not_active Expired - Lifetime
- 1996-09-03 DE DE69625240T patent/DE69625240T2/de not_active Expired - Fee Related
- 1996-09-03 IL IL12405296A patent/IL124052A/xx not_active IP Right Cessation
- 1996-09-03 KR KR1019980702757A patent/KR100482262B1/ko not_active Expired - Fee Related
- 1996-09-03 DE DE0869774T patent/DE869774T1/de active Pending
- 1996-09-03 ES ES96935641T patent/ES2125209T3/es not_active Expired - Lifetime
- 1996-09-03 JP JP9515728A patent/JP2000501380A/ja active Pending
- 1996-09-03 AT AT96935641T patent/ATE228826T1/de not_active IP Right Cessation
- 1996-09-03 PT PT96935641T patent/PT869774E/pt unknown
- 1996-09-03 EP EP06010350A patent/EP1716849A1/de not_active Withdrawn
- 1996-09-03 DK DK96935641T patent/DK0869774T3/da active
- 1996-09-03 AU AU73478/96A patent/AU699080B2/en not_active Ceased
- 1996-09-03 EP EP96935641A patent/EP0869774B1/de not_active Expired - Lifetime
- 1996-09-03 US US09/051,709 patent/US6120787A/en not_active Expired - Fee Related
- 1996-09-03 WO PCT/SE1996/001091 patent/WO1997014408A1/en not_active Ceased
- 1996-09-03 EP EP01117830A patent/EP1142569B1/de not_active Expired - Lifetime
- 1996-09-03 HU HU9901205A patent/HUP9901205A3/hu unknown
- 1996-09-03 AT AT01117830T patent/ATE326953T1/de not_active IP Right Cessation
- 1996-09-03 CZ CZ19981173A patent/CZ293059B6/cs not_active IP Right Cessation
- 1996-09-03 DE DE69636177T patent/DE69636177T2/de not_active Expired - Fee Related
1998
- 1998-04-06 NO NO19981558A patent/NO320392B1/no unknown

Also Published As

Publication number	Publication date
US6120787A (en)	2000-09-19
CZ117398A3 (cs)	1998-09-16
HUP9901205A3 (en)	2001-04-28
NO981558L (no)	1998-04-06
ES2125209T1 (es)	1999-03-01
KR19990064267A (ko)	1999-07-26
AU7347896A (en)	1997-05-07
DK0869774T3 (da)	2003-03-24
DE869774T1 (de)	1999-06-02
EP1142569A2 (de)	2001-10-10
DE69636177D1 (de)	2006-06-29
ES2125209T3 (es)	2003-07-01
SE9503672L (sv)	1997-04-20
SE9503672D0 (sv)	1995-10-19
NO981558D0 (no)	1998-04-06
CZ293059B6 (cs)	2004-01-14
KR100482262B1 (ko)	2006-04-14
PT869774E (pt)	2003-04-30
HUP9901205A2 (hu)	1999-08-30
ATE326953T1 (de)	2006-06-15
DE69636177T2 (de)	2007-03-29
HK1011182A1 (en)	1999-07-09
WO1997014408A1 (en)	1997-04-24
EP1142569B1 (de)	2006-05-24
EP1142569A3 (de)	2003-05-21
DE69625240T2 (de)	2003-09-11
JP2000501380A (ja)	2000-02-08
EP0869774A1 (de)	1998-10-14
SE505146C2 (sv)	1997-06-30
DE69625240D1 (de)	2003-01-16
EP0869774B1 (de)	2002-12-04
ES2267637T3 (es)	2007-03-16
AU699080B2 (en)	1998-11-19
ATE228826T1 (de)	2002-12-15
EP1716849A1 (de)	2006-11-02
IL124052A (en)	2000-11-21

Publication	Publication Date	Title
EP0869774B1 (de)	2002-12-04	Methode zur herstellung von partikeln mit verzoegerter freisetzung
CA2432904C (en)	2007-09-11	Induced phase transition method for the production of microparticles containing hydrophobic active agents
US4623588A (en)	1986-11-18	Controlled release composite core coated microparticles
Vysloužil et al.	2014	The influence of different formulations and process parameters during the preparation of drug-loaded PLGA microspheres evaluated by multivariate data analysis
EP0471036A4 (en)	1992-03-18	Improved encapsulation process and products therefrom
JPH0687758A (ja)	1994-03-29	Ｌｈｒｈホルモンおよびその類似体を徐々に放出する微小球体の製造方法と、その微小球体と、それを含む製剤
RS61209B1 (sr)	2021-01-29	Dobijanje plga mikrosfera napunjenih peptidima sa karakteristikama kontrolisanog oslobađanja
KR20030051687A (ko)	2003-06-25	분자량이 감소된 정제 아밀로펙틴-기제 녹말을 갖는서방투여용 생분해성 미세입자
Tarun et al.	2011	Patented microencapsulation techniques and its application
Wen et al.	2014	Theories and Concepts of Nano Materials, Nano‐and microencapsulation
CA2234615C (en)	2007-11-20	Sustained release particles
Arica et al.	2002	Biodegradable bromocryptine mesylate microspheres prepared by a solvent evaporation technique. I: Evaluation of formulation variables on microspheres characteristics for brain delivery
Chiao et al.	1989	Modification of gelatin beadlets for zero-order sustained release
HK1011182B (en)	2003-06-06	Method for manufacturing sustained release particles
HK1038309B (en)	2007-01-12	Coating of small particles
HK1038309A1 (en)	2002-03-15	Coating of small particles
Khamanga et al.	2017	Science and practice of microencapsulation technology
Philo et al.	2013	Formulation and evaluation of octreotide acetate loaded PLGA microspheres
Roy et al.	2012	Microencapsulation: Convenient mode of drug delivery in novel drug delivery system.
EP1628640A2 (de)	2006-03-01	Durch coazervation hergestellte mikrokapseln mit einem wirkstoff im hüllpolymer
Yeo et al.	2005	Recent advances in microencapsulation technology